Beam Therapeutics (BEAM) Current Assets (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Current Assets data on file, last reported at $1.3 billion in Q1 2026.

• On a quarterly basis, Current Assets rose 1.55% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 1.55% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 44.47% from the prior year.
• Current Assets for Q1 2026 stood at $1.3 billion, roughly flat from $1.3 billion in the prior quarter.
• Over the last five years, Current Assets for BEAM reached as high as $1.3 billion in Q4 2025 and fell as low as $878.1 million in Q4 2024.
• Historically, Current Assets has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2022.
• Across the five-year window, Current Assets soared 140.87% in 2022 and dropped 27.49% in 2024, its largest moves.
• Year by year, Current Assets stood at $1.1 billion in 2022, then gained by 10.81% to $1.2 billion in 2023, then fell by 27.49% to $878.1 million in 2024, then jumped by 44.47% to $1.3 billion in 2025, then decreased by 0.14% to $1.3 billion in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.1 billion in Q3 2025.